No Data
Medicenna Therapeutics GAAP EPS of -C$0.05
Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)
Medicenna Announces Positive Single-Agent Activity of MDNA11 From Dose Expansion Cohort and Encouraging Safety Profile in Combination With KEYTRUDA (Pembrolizumab) at the 39th Annual Meeting of SITC
Bloom Burton Maintains Medicenna Therapeutics(MDNAF.US) With Buy Rating, Maintains Target Price $6
OTC Markets Group Welcomes Medicenna Therapeutics Corp. to OTCQX
Medicenna to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
No Data
No Data